Cotargeting survival signaling pathways in cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• The mammalian target of rapamycin (mTOR) pathway is frequently dysregulated in cancer.
• The relationship between the mTOR pathway and the MAPK cascade (Ras/Raf/MEK/ERK) is not fully understood.
• mTOR inhibitors may activate ERK, suggesting cross-talk between these critical cancer pathways.

Purpose of the Study:

• To investigate the relationship between mTOR signaling and ERK activation in cancer.
• To explore the therapeutic potential of simultaneously inhibiting both pathways.

Main Methods:

• Utilizing prostate and breast cancer cell model systems.
• Analyzing tissue specimens from patients treated with mTOR inhibitors.
• Assessing the effects of combined MEK/ERK and mTOR inhibition in vitro and in vivo.

Main Results:

• Evidence suggests a link between mTOR inhibition and ERK activation, potentially via a negative feedback loop involving S6K1.
• Simultaneous inhibition of MEK/ERK and mTOR significantly enhanced antitumor effects.
• These findings were consistent across both in vitro and in vivo models.

Conclusions:

• Concurrent inhibition of complementary signaling pathways like mTOR and MAPK (ERK) warrants further investigation for cancer treatment.
• Targeting both pathways may offer a more effective therapeutic strategy than targeting either pathway alone.